Loading...
Market
Will Aura Biosciences initiate a Phase 3 trial for Bel-sar in choroidal melanoma by March 31, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
ClinicalTrials.gov and Aura Biosciences press releases
Story
Aura Biosciences Reports Positive Phase 2 Results for Bel-sar in Choroidal Melanoma, 80% Tumor Control Rate
Sep 12, 2024, 11:50 AM
Aura Biosciences has announced positive Phase 2 end-of-study results for its drug Bel-sar, which is being evaluated as a first-line treatment for early-stage choroidal melanoma. The study demonstrated an 80% tumor control rate and a 90% visual acuity preservation rate, with a highly favorable safety profile. These promising results have led to a 7.5% increase in Aura Biosciences' stock price pre-market.
View original story
Similar markets
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
